SAB Biotherapeutics (SABS) Price & Analysis

Compare

184 Followers

SABS Stock Chart & Stats

$3.95

$0.50(13.16%)

At close: Jan 08 4:00 PM EST

$3.95

$0.50(13.16%)

Day’s Range― - ―

52-Week Range$1.00 - $6.60

Previous CloseN/A

Volume58.44K

Average Volume (3M)398.22K

Market Cap

$189.95M

Enterprise Value$17.02M

Total Cash (Recent Filing)$110.88M

Total Debt (Recent Filing)$6.19M

Price to Earnings (P/E)―

Beta0.86

Next Earnings

Mar 26, 2026

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding47,606,850

10 Day Avg. Volume357,955

30 Day Avg. Volume398,221

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)1.35

Price to Sales (P/S)26.55

P/FCF Ratio-1.01

Enterprise Value/Market Cap0.09

Enterprise Value/Revenue148.36

Enterprise Value/Gross Profit-5.60

Enterprise Value/Ebitda0.77

Forecast

1Y Price Target

$12.00

Price Target Upside203.80% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressThe registrational Phase 2b SAFEGUARD trial is actively enrolling patients, indicating progress in clinical development.

Regulatory EndorsementThe Phase 2b SAFEGUARD study has been confirmed by the FDA to potentially serve as a pivotal trial for FDA approval, indicating a significant step towards regulatory endorsement.

Safety ProfileSAB-142 did not induce any cases of serum sickness or anti-drug antibodies, which are common issues with rATG, suggesting a better safety profile.

Bears Say

SAB Biotherapeutics News

SAB Biotherapeutics initiated with a Buy at Guggenheim

Guggenheim initiated coverage of SAB Biotherapeutics (SABS) with a Buy rating and $15 price target The company’s lead...

1d ago

SABS

SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial

SAB Biotherapeutics (SABS) announced the dosing of the first patient with SAB-142 in the Phase 2b registrational SAFety...

2d ago

SABS

SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint

SAB Biotherapeutics (SABS) announced positive, confirmatory data from a Phase 1 trial of SAB-142 in a single- and...

3d ago

SABS

Eleven new option listings and two option delistings on December 8th

New option listings for December 8th include Cboe Magnificent 10 Index (.MGTN), Leverage Shares 2x Long ABNB Daily...

12d ago

DOOO

SAB Biotherapeutics to present data on progress in development of SAB-142

SAB Biotherapeutics (SABS) announced that the Company will give several oral presentations at the 2nd Asian Conference on...

12d ago

SABS

SAB Biotherapeutics: Favorable SAB-142 Safety Profile and De-Risked Phase 2b Design Underpin Buy Rating

In a report released on December 17, Emily Bodnar from H.C. Wainwright maintained a Buy rating on SAB...

23h ago

SABS

SAB Biotherapeutics Reports Positive Q3 2025 Earnings

Sab Biotherapeutics, Inc. ( ($SABS) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

SABS

Sab Biotherapeutics, Inc. (SABS) Q3 Earnings Cheat Sheet

Sab Biotherapeutics, Inc. (SABS) is scheduled to report 3rd quarter earnings on 11/18/2025. Regarding Q3 estimates, Wall Street...

1M ago

SABS

Promising Clinical Developments and Strategic Decisions Justify Buy Rating for SAB Biotherapeutics

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on SAB Biotherapeutics. The associated price target...

1M ago

SABS

Promising Phase 1 Data for SAB-142 Supports Buy Rating for SAB Biotherapeutics

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on SAB Biotherapeutics, with...

1M ago

SABS

Sab Biotherapeutics’ New Study Targets Type 1 Diabetes Progression

Sab Biotherapeutics, Inc. (($SABS)) announced an update on their ongoing clinical study. Study Overview: Sab Biotherapeutics, Inc. is...

2M ago

SABS

SAB Biotherapeutics Board Members Resign in Agreement

SAB Biotherapeutics ( ($SABS) ) has provided an announcement. On September 30, 2025, Christine Hamilton and Jeffrey Spragens...

3M ago

SABS

SAB Biotherapeutics Approves Equity Plan Amendments

SAB Biotherapeutics ( ($SABS) ) has issued an announcement. On September 26, 2025, SAB Biotherapeutics held a special...

3M ago

SABS

Promising Developments and Strategic Partnerships Drive Buy Rating for SAB Biotherapeutics’ SAB-142

Emily Bodnar, an analyst from H.C. Wainwright, reiterated the Buy rating on SAB Biotherapeutics. The associated price target...

3M ago

SABS

SABS FAQ

What was SAB Biotherapeutics’s price range in the past 12 months?

SAB Biotherapeutics lowest stock price was $1.00 and its highest was $6.60 in the past 12 months.

What is SAB Biotherapeutics’s market cap?

SAB Biotherapeutics’s market cap is $189.95M.

When is SAB Biotherapeutics’s upcoming earnings report date?

SAB Biotherapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 96 days.

How were SAB Biotherapeutics’s earnings last quarter?

SAB Biotherapeutics released its earnings results on Nov 13, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.378 by $0.168.

Is SAB Biotherapeutics overvalued?

According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SAB Biotherapeutics pay dividends?

SAB Biotherapeutics does not currently pay dividends.

What is SAB Biotherapeutics’s EPS estimate?

SAB Biotherapeutics’s EPS estimate is -0.2.

How many shares outstanding does SAB Biotherapeutics have?

SAB Biotherapeutics has 47,606,850 shares outstanding.

What happened to SAB Biotherapeutics’s price movement after its last earnings report?

SAB Biotherapeutics reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.378. Following the earnings report the stock price went up 4.516%.

Which hedge fund is a major shareholder of SAB Biotherapeutics?

Currently, no hedge funds are holding shares in SABS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

SAB Biotherapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-21.16%

Trailing 12-Months

Asset Growth

-51.32%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

SAB Biotherapeutics

SAB Biotherapeutics (SABS) is a biotechnology company focused on developing and commercializing therapeutic products derived from its proprietary platform utilizing immunoglobulin-producing animals. The company operates primarily in the biopharmaceutical sector, specializing in the production of polyclonal antibodies for the treatment of various diseases, including infectious diseases, autoimmune disorders, and cancer. SAB's core products include SAB-176, a therapeutic candidate for COVID-19, and other antibody therapies in various stages of development.

SAB Biotherapeutics (SABS) Earnings & Revenues

Historic Earnings Reports

SABS Stock 12 Month Forecast

Average Price Target

$12.00

▲(203.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.79,4.6523076923076925,5.514615384615385,6.376923076923077,7.239230769230769,8.10153846153846,8.963846153846154,9.826153846153847,10.688461538461539,11.55076923076923,12.413076923076922,13.275384615384617,14.137692307692308,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.79,4.421538461538462,5.053076923076923,5.684615384615385,6.3161538461538465,6.947692307692308,7.57923076923077,8.21076923076923,8.842307692307692,9.473846153846154,10.105384615384615,10.736923076923077,11.368461538461538,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.79,4.190769230769231,4.591538461538462,4.992307692307692,5.393076923076923,5.793846153846154,6.194615384615385,6.595384615384615,6.996153846153846,7.396923076923077,7.797692307692308,8.198461538461538,8.599230769230768,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >